首页/数据集/Chronicle of regulatory actions and safety information related to ESAs.

Chronicle of regulatory actions and safety information related to ESAs.

Figshare2020-06-25 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Chronicle_of_regulatory_actions_and_safety_information_related_to_ESAs_/12566987 数据链接链接失效反馈

官方服务：

资源简介：

Chronicle of regulatory actions and safety information related to ESAs.

应用场景：

创建时间：

2020-06-25

治疗策略优化

药物安全监测

Data from Chemistry Results Form [CRF 11, serum electrolytes and creatinine testing results table] Study Description A randomized, proof-of-concept study of adolescents and young adults aged 18-24 yea

NIAID Data Ecosystem70

Reasons of occurring severe adverse events.

药物安全监测

不良事件分析

(DOCX)

NIAID Data Ecosystem60

A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database

药物不良反应

药物安全监测

Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+ advanced/metastatic breast cancer. This study comprehensively analyzed its adverse reaction profile using FDA Adverse Event Reporting

Taylor & Francis Group2025-12-05 更新50

Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database

药物安全监测

不良事件分析

Fostamatinib, an FDA-approved oral small-molecule spleen tyrosine kinase (SYK) inhibitor, is used to treat thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have not responded

DataCite Commons2026-04-23 更新60

Post-marketing safety of panitumumab: a real-world pharmacovigilance study

药物安全监测

抗癌药物不良反应

Panitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S. Food and Drug Admini

NIAID Data Ecosystem50

Chronicle of regulatory actions and safety information related to ESAs.

资源简介：

相关数据集